Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00502398
Recruitment Status : Unknown
Verified October 2007 by Rabin Medical Center.
Recruitment status was:  Recruiting
First Posted : July 17, 2007
Last Update Posted : October 16, 2007
Information provided by:
Rabin Medical Center

Brief Summary:

Patients with hemolytic disorders (e.g. sickle cell anemia or thalassemia) are known to develop pulmonary hypertension. Hemolysis is where red blood cells are destroyed and their contents released into the circulation. It is thought that these red-cell contents cause constriction and thrombosis of the blood vessels in the lungs. Conversely, it is possible that patients with pulmonary hypertension have hemolysis.

In this study we will be drawing blood from a range of patients and normal controls for a panel of blood tests related to hemolysis.

Condition or disease Intervention/treatment
Pulmonary Artery Hypertension Procedure: Blood test

Study Type : Observational
Time Perspective: Prospective
Study Start Date : September 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

One of the following four conditions :

  • Pulmonary artery hypertension
  • Obstructive sleep apnea with pulmonary hypertension
  • Lung transplant candidates without pulmonary hypertension
  • Normal Controls

Exclusion Criteria:

  • Known hemolytic disorder
  • Recent blood loss (<3 months)
  • Recent blood transfusion (<3 months)
  • Liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00502398

Contact: Ben Fox, MRCP +972 3 937 7221

Pulmonary Institute, Rabin Medical Center (Beilinson campus) Recruiting
Petach Tikva, Israel, 49100
Contact: Ben Fox, MRCP   
Sponsors and Collaborators
Rabin Medical Center
Principal Investigator: Mordechai Kramer, MD Rabin Medical Center Identifier: NCT00502398     History of Changes
Other Study ID Numbers: RMC074490CTIL
First Posted: July 17, 2007    Key Record Dates
Last Update Posted: October 16, 2007
Last Verified: October 2007

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases